CAPROCK Group Inc. bought a new stake in Dynavax Technologies Corporation (NASDAQ:DVAX) during the second quarter, Holdings Channel reports. The institutional investor bought 13,890 shares of the biopharmaceutical company’s stock, valued at approximately $134,000.

Several other institutional investors also recently added to or reduced their stakes in the company. Parametric Portfolio Associates LLC increased its stake in Dynavax Technologies Corporation by 3.6% in the first quarter. Parametric Portfolio Associates LLC now owns 27,151 shares of the biopharmaceutical company’s stock worth $162,000 after buying an additional 939 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Dynavax Technologies Corporation by 3.9% in the first quarter. Bank of New York Mellon Corp now owns 176,996 shares of the biopharmaceutical company’s stock worth $1,053,000 after buying an additional 6,623 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in Dynavax Technologies Corporation during the first quarter worth about $121,000. Falcon Point Capital LLC increased its stake in Dynavax Technologies Corporation by 57.5% in the first quarter. Falcon Point Capital LLC now owns 117,568 shares of the biopharmaceutical company’s stock worth $700,000 after buying an additional 42,929 shares during the last quarter. Finally, C WorldWide Group Holding A S increased its stake in Dynavax Technologies Corporation by 8.1% in the first quarter. C WorldWide Group Holding A S now owns 284,082 shares of the biopharmaceutical company’s stock worth $1,690,000 after buying an additional 21,313 shares during the last quarter. 56.05% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) opened at 18.65 on Wednesday. Dynavax Technologies Corporation has a 52 week low of $3.20 and a 52 week high of $19.60. The stock has a 50 day moving average of $10.50 and a 200 day moving average of $6.66. The stock’s market cap is $926.91 million.

Dynavax Technologies Corporation (NASDAQ:DVAX) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.09. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 101.98%. The company had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.15 million. During the same quarter in the previous year, the company posted ($0.75) EPS. On average, analysts expect that Dynavax Technologies Corporation will post ($1.18) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This story was originally published by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.dailypolitical.com/2017/08/09/caprock-group-inc-invests-134000-in-dynavax-technologies-corporation-nasdaqdvax.html.

A number of research firms recently issued reports on DVAX. Royal Bank Of Canada set a $7.00 price target on shares of Dynavax Technologies Corporation and gave the company a “hold” rating in a research note on Wednesday, July 26th. Zacks Investment Research downgraded shares of Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. ValuEngine downgraded shares of Dynavax Technologies Corporation from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies Corporation in a research note on Thursday, July 27th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $45.00 price target on shares of Dynavax Technologies Corporation in a research note on Thursday, July 27th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $23.67.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Corporation (NASDAQ:DVAX).

Institutional Ownership by Quarter for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.